GLP1R and synucleinopathy: With multiple previous studies demonstrating GLP-1R agonists’ therapeutic modulation of microglia, particularly in CNS disease models, we selected a pegylated, long-acting exenatide, NLY01, which directly regulates activated microglia with favorable downstream effect on neurodegeneration, both in the α-synuclein preformed fibril mouse model of Parkinson’s disease as well as in the human A53T α-synuclein transgenic mouse model of α-synucleinopathy–induced neurodegeneration (18).